目的 采用星点设计-效应面法优化叶黄素温敏凝胶处方,并对其体外释放行为进行考察。方法 以胶凝温度为评价指标,考察泊洛沙姆407(P407)和泊洛沙姆188(P188)用量对胶凝温度的影响,使用星点设计-效应面法进行优化,再通过无膜溶出法考察凝胶溶蚀及药物释放。结果 P407及P188用量两个影响因素与胶凝温度之间存在定量关系,最佳处方:P407质量浓度为0.21 g·mL-1,P188质量浓度为0.03 g·mL-1,凝胶溶蚀及药物释放符合零级动力学方程。结论 所建立的模型预测性良好,可用于叶黄素原位凝胶处方的预测及优化。
Abstract
OBJECTIVE To optimize the formulation of the lutein thermosensitive in situ gels by using central composite design-response surface methodology, and study the drug release in vitro. METHODS Gelation temperature was served as the indicator. The influences of the amounts of Poloxamer 407 and Poloxamer 188 on the gelation temperature were investigated. Central composite design-response surface method was used to optimize the prescription. The drug release profile of the preparation was investigated with a membrane-less dissolution model. RESULTS The amounts of Poloxamer 407 and Poloxamer 188 had quantitative relationships with the gelation temperature. The optimum prescription was as follows: the mass concentration of P407 was 0.21 g·mL-1, and the mass concentration of P188 was 0.03 g·mL-1. The dissolution and drug release of the gels followed zero-order kinetics equation. CONCLUSION Central composite design-response surface methodology can be applied to optimize the formulation of the lutein thermosensitive in situ gels.
关键词
叶黄素 /
温敏型原位凝胶 /
星点设计-效应面法 /
无膜溶出
{{custom_keyword}} /
Key words
lutein /
thermosensitive in situ gels /
central composite design-response surface methodology /
membrane-less dissolution
{{custom_keyword}} /
中图分类号：
R944
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] WANG L J, ZHU Z J, WU Q, et al. Optimization of ibuprofen slowly-released in situ gel by uniform design and studies of release behavior [J]. J Chongqing Med Univ(重庆医科大学学报), 2009,34(12):1704-1708.
[2] ZHU D D, ZHANG Y G, ZHOU R. Preparation of pilocarpine thermosensitive gel and study on dissolution performance[J]. Cent South Pharm(中南药学), 2009,7(10):728-731.
[3] GAO F, WANG D K, LUO L, et al. Preparation of levofloxacin thermosensitive ocular gel and study on drug release in vitro[J]. J China Pharm(中国药房), 2005,16(14):1057-1059.
[4] KRINSKY N I . Possible biologic mechanisms for a protective role of xanthophylls[J]. J Nutr, 2002,132(3):540-542.
[5] ZHU H X, ZHENG J X. A review: Structure, distribution, properties and physiological functions of lutein[J]. China Food Add(中国食品添加剂), 2005 (5):48-55.
[6] HAN J. Preparation process of a kind of water-soluble lutein: China. CN102475696A[P].2012,5:50.
[7] AMIJI M M, LAI P K, DINESH B, et al. Intratumoral administration of paclitaxel in an in situ gelling poloxamer 407 formulation[J]. Pharm Dev Technol, 2002, 7(2):195-202.
[8] HU Y J, SONG L, TIAN P C. Preparation and drug release in vitro of ocular acyclovir in-situ gels[J]. Anhui Med Pharm J(安徽医药), 2014,18(1):30-32.
[9] XIA M F, LIANG W Q, LI S M, et al. Study on the formulation of compound neostigmine in situ ophthalmic gel[J]. Chin J Mod Appl Pharm, 2014,31(6):711-713.
[10] DESAI S D, BLANCHARD J. In vitro evaluation of pluronic F127-based controlled release ocular delivery systems for pilocarpine[J]. Pharm Sci,1998,87(2):2261.
[11] MA S W, GAN Y, GAN L, et al. Preparation and in vitro corneal retention behavior of novel cationic microemulsion/in situ gel system[J]. Acta Pharm Sin(药学学报), 2008,43(7):749-755.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
沈阳市科技创新专项基金资助项目(F15-199-1-25)
{{custom_fund}}
PDF(967 KB)
